PHXM — Phaxiam Therapeutics SA Cashflow Statement
0.000.00%
Last trade - 00:00- €22.16m
- €24.95m
- €1.33m
Annual cashflow statement for Phaxiam Therapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -62.7 | -73.3 | -53.8 | -0.228 | -23.5 |
| Depreciation | |||||
| Non-Cash Items | 0.219 | 5.78 | -1.2 | -28.6 | 0.841 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 14.9 | 10.8 | -7.15 | -7.58 | -2.57 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -43.3 | -51.7 | -56.8 | -31.8 | -24.4 |
| Capital Expenditures | -20.1 | -1.14 | -0.298 | -0.085 | -0.217 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.279 | -0.336 | -0.047 | 38.2 | 0.388 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -19.8 | -1.48 | -0.345 | 38.1 | 0.171 |
| Financing Cash Flow Items | 1.71 | -0.138 | -0.374 | -0.223 | 0.061 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.04 | 25.4 | 44.7 | -1.77 | -3.72 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -61.2 | -28.7 | -10.7 | 5.09 | -28.3 |